Cargando…
Human microbiome signatures of differential colorectal cancer drug metabolism
It is well appreciated that microbial metabolism of drugs can influence treatment efficacy. Microbial β-glucuronidases in the gut can reactivate the excreted, inactive metabolite of irinotecan, a first-line chemotherapeutic for metastatic colorectal cancer. Reactivation causes adverse drug responses...
Autores principales: | Guthrie, Leah, Gupta, Sanchit, Daily, Johanna, Kelly, Libusha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665930/ https://www.ncbi.nlm.nih.gov/pubmed/29104759 http://dx.doi.org/10.1038/s41522-017-0034-1 |
Ejemplares similares
-
Bringing microbiome-drug interaction research into the clinic
por: Guthrie, Leah, et al.
Publicado: (2019) -
The human gut chemical landscape predicts microbe-mediated biotransformation of foods and drugs
por: Guthrie, Leah, et al.
Publicado: (2019) -
Colorectal Cancer-Associated Microbiome Patterns and Signatures
por: Zhao, Lan, et al.
Publicado: (2021) -
Metabolism, microbiome and colorectal cancer
por: Datta, Somenath, et al.
Publicado: (2017) -
Differential Mucosal Microbiome Profiles across Stages of Human Colorectal Cancer
por: Zhang, Mingqing, et al.
Publicado: (2021)